BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28242198)

  • 1. miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
    Qiao W; Guo B; Zhou H; Xu W; Chen Y; Liang Y; Dong B
    Biochem Biophys Res Commun; 2017 Apr; 486(1):43-48. PubMed ID: 28242198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
    She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
    Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-300 inhibited glioblastoma progression through ROCK1.
    Zhou F; Li Y; Hao Z; Liu X; Chen L; Cao Y; Liang Z; Yuan F; Liu J; Wang J; Zheng Y; Dong D; Bian S; Yang B; Jiang C; Li Q
    Oncotarget; 2016 Jun; 7(24):36529-36538. PubMed ID: 27145462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
    Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
    Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
    Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
    Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.
    Wang X; Li J; Xu X; Zheng J; Li Q
    Biomed Pharmacother; 2018 Jul; 103():1312-1318. PubMed ID: 29864913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
    Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
    Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A.
    Chang X; Zhang H; Lian S; Zhu W
    Biochem Biophys Res Commun; 2016 Jul; 475(3):251-6. PubMed ID: 27233613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
    Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
    J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
    Zhang C; Yang X; Fu C; Liu X
    Gene; 2018 Sep; 672():172-179. PubMed ID: 29906532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
    She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Luo Z; Li G; Wu M
    Med Oncol; 2014 Apr; 31(4):892. PubMed ID: 24573637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
    Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
    Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
    Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
    Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
    Lan F; Yu H; Hu M; Xia T; Yue X
    J Neurochem; 2015 Oct; 135(2):274-86. PubMed ID: 26250785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
    Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK
    Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
    Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M
    Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.